
               
               
               7 DRUG INTERACTIONS
               
                  Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John’s wort) may significantly decrease exposure to exemestane. Dose modification is recommended for patients who are also receiving a strong CYP 3A4 inducer [
                     see Dosage and Administration
                     (
                     2.2
                     )
                     and Clinical Pharmacology
                     (
                     12.3
                     )].
               
               
               
                  
                     
                        •Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. Increase the exemestane dose to 50 mg (2.2, 7). 
                     
                  
               
            
         